DiaMedica Enrolls 200th Patient in Phase 2/3 Stroke Trial

By Public Technologies
  • DiaMedica Therapeutics enrolled the 200th patient in its Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) for acute ischemic stroke.
  • The enrollment milestone triggers a planned interim analysis, with results expected in the first quarter of 2027.
  • An independent safety board will assess whether to resize the trial or stop it for futility following participants' 90-day follow-up.
  • If the trial continues, final enrollment will range from 300 to 728 participants.
  • Recruitment will continue during the review; DiaMedica will remain blinded to interim data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DiaMedica Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220800BIZWIRE_USPR_____20261022_BW903912) on October 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.